撰文丨王聪 编辑丨王多鱼 排版丨水成文 三阴性乳腺癌 （TNBC） ，其特征为雌激素受体 （ER） 、孕激素受体 （PR） 和人表皮生长因子受体 2 （HER2） 均缺失，占所有浸润性乳腺癌的 15% 至 20%，且相较于其他乳腺癌亚型，其早期复发的风险更高，是 乳腺癌中最凶险的亚型。 近日，复旦大学附属肿瘤医院 邵志敏 团队在国际顶尖医学期刊《 英国医学杂志 》 （BMJ） 上发表了题为： Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial 的论文研究论文。 这项 3 期临床试验证实，在以蒽环类/紫杉烷类为基础的 辅助化疗 中加入 卡铂 ，显著改善了高危早期 三阴性乳腺癌 患者的生存结局，将患者的三年无病生存率 从 85.8% 提升至 92 ...

Summary of Hims & Hers Health Conference Call Company Overview - **Company**: Hims & Hers Health (NYSE:HIMS) - **Date**: March 02, 2026 - **Focus**: The company aims to make treatment for stigmatized conditions accessible and enhance consumer awareness. Key Points Industry and Market Position - Hims & Hers has evolved from focusing on awareness and access to personalized treatments, investing hundreds of millions in capital expenditures to enhance capabilities [2][3][4] - The company has over 2.5 million subscribers, allowing it to analyze consumer journeys from intent to outcome [4] Strategic Vision and Growth - Future strategy will leverage historical competencies while aggressively utilizing data to enhance personalized treatments and remove friction points in the consumer journey [5] - Plans for international expansion have been reinforced by recent acquisitions, including Eucalyptus, and a focus on markets like Canada and the UK [9][10] Financial Performance and Projections - The company aims for a revenue target of $6.5 billion and $1.3 billion in EBITDA by 2030 [24] - Each new specialty is projected to achieve a run rate of over $100 million in the near future, with significant market potential in the U.S. and globally [22][23] Marketing and Brand Development - Marketing efficiency improved significantly, with a 7-point increase in marketing as a percentage of revenue year-over-year [12] - The company aims to become the default brand for health and wellness, similar to how consumers associate specific brands with other industries [13][14] New Specialties and Innovations - Focus on recurring conditions and emotionally resonant issues, such as low testosterone and menopause, to drive growth [18][19] - Introduction of at-home diagnostic devices and AI integration to enhance consumer experience and treatment personalization [9][48] International Strategy - The company has a history of international operations and is leveraging domestic cash flow to fund international growth [29][30] - The international market is expected to reach at least $1 billion in revenue in the coming years, with a focus on adapting to local regulatory environments [36] Competitive Landscape - Hims & Hers differentiates itself through a strong brand, extensive subscriber base, and a robust provider network, which enhances its competitive position against larger organizations like Amazon [55][56][57] Challenges and Future Outlook - The company is navigating challenges in the sexual health market but expects to see growth resume in the latter half of the year [40][41] - Continuous monitoring of new specialties and their integration into the platform will be crucial for sustained growth [41][42] Technology and AI Integration - Investments in technology are aimed at improving operational efficiency and enhancing the consumer experience through personalized care and diagnostics [46][50] - The introduction of AI-driven tools, such as care coaches, is expected to further enhance user engagement and treatment outcomes [50][51] Conclusion Hims & Hers Health is strategically positioned for growth through its focus on personalized treatments, international expansion, and technological innovation. The company aims to solidify its brand presence in the health and wellness sector while navigating market challenges and leveraging data-driven insights to enhance consumer experiences.

Company Overview - Tianchen Biopharmaceutical (Suzhou) Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of biologics for allergic and autoimmune diseases [3] - The company has two main products: LP-003, an anti-IgE antibody for treating allergic diseases, and LP-005, a dual-function antibody targeting complement proteins C5 and C3b [3][4] - LP-003 has shown significant efficacy in clinical trials for chronic spontaneous urticaria (CSU) and moderate to severe seasonal allergic rhinitis (AR) [3][4][12] - LP-005 has received IND approvals for multiple indications, including paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated kidney diseases, and is currently undergoing clinical trials in China [4] Financial Information - The company reported revenues of RMB 2.33 million, RMB 3.07 million, RMB 2.17 million, and RMB 2.397 million for the fiscal years 2023, 2024, and the nine months ending September 30 for 2024 and 2025, respectively [5][6] - The total loss for the fiscal years 2023, 2024, and the nine months ending September 30 for 2024 and 2025 was RMB 95.778 million, approximately RMB 137.321 million, RMB 92.334 million, and approximately RMB 137.575 million, respectively [5][6] Industry Overview - The global market for allergic disease medications has grown from USD 42.8 billion in 2018 to an expected USD 68.8 billion by 2024, with a CAGR of 8.2%, projected to reach USD 111.4 billion by 2030 [6][7] - In China, the market for allergic disease medications is expected to grow from USD 3.8 billion in 2018 to USD 8.1 billion by 2024, with a CAGR of 13.3%, and projected to reach USD 22.9 billion by 2030 [7] - The market share of biologics in the global allergic disease medication market is expected to increase from 40.4% in 2024 to 61.3% by 2030 [6] - The market for anti-IgE antibody medications in China is projected to grow from RMB 1 billion in 2018 to RMB 2 billion by 2024, and further to RMB 12.1 billion by 2030, with a CAGR of 32.5% [7][10]

Core Viewpoint - The article discusses a novel urine liquid biopsy method developed to enhance the prediction of bladder cancer patients' responses to surgery and Bacillus Calmette-Guérin (BCG) treatment, addressing the limitations of current diagnostic methods due to the "field effect" [3][6][17]. Group 1: Background and Challenges - Non-muscle invasive bladder cancer (NMIBC) is a common type where patients typically undergo tumor resection followed by BCG immunotherapy, but BCG is not effective for all patients, and predictive biomarkers are lacking [6]. - Urine tumor DNA (utDNA) analysis is a non-invasive monitoring method, but the presence of somatic mutations in normal urothelial cells near tumors leads to false positives due to the "field effect," which acts as background noise [6][5]. Group 2: Innovative Methodology - The research team developed a statistical method named RePhyNERX to filter out mutations likely caused by the "field effect" by comparing tumor samples with normal tissues or post-treatment urine, significantly improving the specificity of utDNA detection [8][7]. - In a training cohort, the use of post-treatment urine for filtering yielded the best results, effectively distinguishing patient prognoses with a hazard ratio (HR) of 12.6, indicating a reduction in false positives [8]. Group 3: Clinical Validation - The study prospectively collected urine samples from 61 NMIBC patients undergoing BCG treatment, analyzing samples before surgery, before BCG treatment, and after treatment [10]. - Patients were categorized into three molecular response types: 1. Complete surgical responders: 39.3% had negative utDNA post-surgery, potentially curable by surgery alone 2. BCG responders: 27.9% had positive utDNA pre-treatment but significant decline post-treatment 3. Non-responders: 32.8% had persistent or rising utDNA post-treatment [10][11]. Group 4: Molecular Mechanisms - The research identified biomarkers distinguishing surgical responders from BCG responders, noting that BCG responders had a higher tumor mutation burden (TMB) and enriched immune-related gene expression, indicating a pre-existing immune activation environment is necessary for BCG efficacy [13][12]. - A high T cell/stroma enrichment score (TSE) correlated positively with BCG response, similar to predictive markers for immune checkpoint inhibitors [14]. Group 5: Future Prospects - This research not only improves the accuracy of urine liquid biopsy but also paves the way for personalized treatment strategies, allowing utDNA negative patients to potentially avoid unnecessary BCG treatment and reducing side effects, while positive patients can receive early intensified treatment [17]. - The method has potential applications in other cancers, such as lung and head and neck cancers, addressing the "field effect" issue [18].

据港交所1月21日披露，北京普祺医药科技股份有限公司(简称：普祺医药)向港交所主板递交上市申请书，中信证券、民银资本为联席保荐人。 公司简介 招股书显示，普祺医药是一家专注于免疫炎症领域的生物科技(Biotech)公司，致力于成为局部递送靶向疗法的领导者。公司自2016年成立以来，以创新原创 设计及精准局部递送为核心能力，深耕慢性炎症性疾病治疗领域，旨在提供兼具疗效、安全性及长期患者满意度的创新解决方案。 基于对免疫炎症相关信号通路的深入了解，公司发现：多种慢性疾病的核心病理进程，与细胞外免疫信号传递及转录调控(以Janus激酶-信号转导及转录激活 因子("JAK-STAT")通路为代表)及免疫细胞活化调控通路的协同作用高度相关，并基于此洞察形成了具备同类首创潜力的创新产品管线，凭借原创设计分 子，针对多个存在重大未满足医疗需求的适应症进行布局。 凭借对这些信号通路的深入理解以及综合创新药物研发体系，普祺医药开发了后期核心产品PG-011(普美昔替尼)，其有两种剂型，包括针对特应性皮炎的普 美昔替尼凝胶与针对过敏性鼻炎的普美昔替尼鼻喷雾剂。公司亦拥有多元化候选产品组合，包括针对瘙痒症的PG-033片剂、针对自 ...

智通财经APP获悉，据港交所1月21日披露，北京普祺医药科技股份有限公司(简称：普祺医药)向港交所主板递交上市申请书，中信证券、民银资本为联席保 荐人。 公司简介 招股书显示，普祺医药是一家专注于免疫炎症领域的生物科技(Biotech)公司，致力于成为局部递送靶向疗法的领导者。公司自2016年成立以来，以创新原创 设计及精准局部递送为核心能力，深耕慢性炎症性疾病治疗领域，旨在提供兼具疗效、安全性及长期患者满意度的创新解决方案。 基于对免疫炎症相关信号通路的深入了解，公司发现：多种慢性疾病的核心病理进程，与细胞外免疫信号传递及转录调控(以Janus激酶-信号转导及转录激活 因子("JAK-STAT")通路为代表)及免疫细胞活化调控通路的协同作用高度相关，并基于此洞察形成了具备同类首创潜力的创新产品管线，凭借原创设计分 子，针对多个存在重大未满足医疗需求的适应症进行布局。 凭借对这些信号通路的深入理解以及综合创新药物研发体系，普祺医药开发了后期核心产品PG-011(普美昔替尼)，其有两种剂型，包括针对特应性皮炎的普 美昔替尼凝胶与针对过敏性鼻炎的普美昔替尼鼻喷雾剂。公司亦拥有多元化候选产品组合，包括针对瘙痒症的P ...

Core Viewpoint - Obesity has become a global health challenge affecting over 650 million adults, and traditional weight loss interventions show significant variability in effectiveness among individuals. A new predictive tool combining genetic information and physiological parameters has been developed to enhance personalized obesity treatment [6][9]. Research Background - Traditional BMI-based obesity classification fails to reveal individual differences in appetite regulation and energy metabolism, leading to inconsistent drug treatment outcomes. Current FDA-approved weight loss medications show up to threefold differences in effectiveness among individuals, highlighting the need for more precise efficacy prediction methods [9]. - The study focuses on the quantifiable physiological indicator of "satiety" through deep phenotyping and polygenic risk scoring, aiming to establish a personalized treatment prediction model [9]. Research Methodology - The study included 717 obese patients (BMI ≥ 30 kg/m²), with an average age of 41.1 years and average BMI of 37.0 kg/m². A standardized breakfast was consumed after an overnight fast, followed by a test to measure total caloric intake at maximum satiety [10]. - Genetic analysis involved extracting DNA from leukocytes and using the OmniExome v2.5 chip to detect 2637 loci, focusing on 41 obesity-related genes. Machine learning methods were employed to construct a satiety prediction model [11]. - Two randomized controlled trials were designed to validate the model, assessing weight changes in response to medications over specified periods [11]. Research Results 1. **Drivers of Satiety Variability**: Significant differences in caloric intake for satiety were observed, with males requiring more calories than females. Traditional body composition and metabolic rate indicators had limited explanatory power [12]. 2. **Establishment and Validation of Genetic Risk Score**: The genetic risk score (CTSGRS) showed a strong correlation with average satiety levels in training and validation cohorts, with specific gene variants contributing significantly to predictions [13]. 3. **Predictive Ability of Genetic Risk Score**: The machine learning-derived CTSGRS demonstrated excellent predictive performance, with AUC values indicating strong reliability in both training and validation phases [14]. 4. **Individualized Drug Response Prediction**: The study revealed significant individual differences in drug response, with specific patient profiles responding better to certain medications based on their CTS and CTSGRS levels [15]. Research Conclusion - The study successfully integrated genetic and physiological data to create a predictive model for obesity treatment. Key findings include the genetic basis of satiety differences, the strong predictive capability of the CTSGRS, and the variability in drug response among individuals [16]. Clinical Significance - This research marks a significant advancement in obesity precision classification, with the CTSGRS aiding clinical decision-making and potentially improving the efficacy of personalized medication strategies. Future work may optimize the model for broader weight loss interventions and explore gene-drug interactions for comprehensive obesity management [18].

Group 1 - The global healthcare industry is entering a structural reshaping period by 2025, driven by technological breakthroughs, payment reforms, and digitalization, shifting focus from scale expansion to value creation and precision medicine [1] - The Chinese market is experiencing growth driven by healthcare insurance reforms and health consumption upgrades, while globally, companies face innovation pressures and capital constraints, necessitating clearer strategic focus to navigate uncertainties [1] - The rapid rise of GLP-1 drugs is reshaping the global healthcare industry, significantly reducing the risk of various chronic diseases but also causing structural anxiety among healthcare providers due to anticipated declines in clinical service demand, impacting industry profit models [2] Group 2 - The radioactive drug industry is emerging as a new "golden track" following ADC and GLP-1, showing breakthrough potential in precision diagnosis and treatment of major diseases, with the Chinese market poised for rapid expansion driven by substantial patient demand [6] - Post-COVID, health anxiety persists, with new technologies and products encouraging consumers to shift from passive treatment to proactive health management, creating new growth logic and innovation space for the healthcare industry in China [8] - Pharmaceutical companies are transitioning from a product-centric growth model to providing systematic solutions, integrating the entire value chain and fostering collaborative innovation to redefine their roles and growth logic within the healthcare system [12] Group 3 - Cardiovascular diseases represent a core long-term pressure on healthcare systems in China and globally, with a large patient base that continues to grow with population aging, necessitating enhanced prevention, diagnosis, and long-term management capabilities [13] - The Chinese healthcare industry is entering a new phase of high-quality, full-chain development driven by consumption upgrades and population aging, with the medical service market expected to reach 10 trillion yuan by 2030, becoming a significant growth engine for the Chinese economy [17] - Hospitals are accelerating digitalization and AI applications to enhance operational resilience and patient experience, with those that can flexibly restructure processes around patient needs likely to gain competitive advantages in the new growth cycle [18] Group 4 - The healthcare industry is transitioning from standardized medication to highly personalized treatment, with cell and gene therapy (CGT) emerging as a core innovation force, necessitating systemic restructuring around distribution, payment, and delivery models [22] - There is a significant gap in medical research focused on women's health, with only 7% of studies addressing women's diseases, highlighting the need to bridge this systemic disparity to unlock substantial social and economic value [23] - Many consumers understand the importance of health but struggle with daily life challenges that hinder healthy choices, indicating that true health consumption opportunities lie in designing products and services that seamlessly integrate healthy choices into everyday life [26] Group 5 - In a challenging environment marked by profit pressures, R&D uncertainties, and intensified competition, biopharmaceutical companies must focus on a few decisive issues to avoid strategic blind spots and maintain long-term performance [27] - The integration of artificial intelligence and value-based healthcare has the potential to transform the healthcare industry, overcoming fragmentation and driving systemic upgrades focused on outcomes [31] - The next wave of innovation in immunotherapy is shifting from single blockbuster drugs to multi-mechanism, cross-indication advancements, with future growth relying on breakthroughs in new targets and the redefinition of efficacy standards [32]

美国密歇根州立大学研究团队利用捐赠的人类干细胞，成功开发出全球首个"人源化"心脏类器官，能在 暴露于炎症环境时表现出心房颤动特征。这一突破为研究心律失常提供了前所未有的活体人体组织模 型，有望打破该领域30多年来无新药问世的僵局。这项发表于《细胞·干细胞》的研究，标志着人类在 对抗心律失常的道路上迈出了关键一步。 心房颤动影响全球约6000万人，但由于缺乏准确的人类心脏模型，药物研发长期停滞。近30多年来，没 有新药物被开发用于治疗心房颤动。现有疗法往往针对症状而非潜在机制，因此人们对这种疾病仍然治 疗不力。 2020年起，密歇根州立大学发育与干细胞生物学部艾托·阿吉雷团队利用捐赠的人类干细胞，培育出直 径约数毫米的三维心脏类器官。这些类器官不仅拥有类似真实心脏的腔室结构和血管网络，还能自主节 律性跳动。而且这些类器官的节律性搏动非常强劲，无需显微镜即可观察到。 类器官大小与扁豆相仿，精确度极高，使团队能够以前所未有的方式研究心脏发育、疾病和药物反应。 此次研究的关键进展在于，团队首次在类器官中引入了免疫细胞。博士后研究员科林·奥罗克发现，当 类器官暴露于炎症环境时，会出现类似房颤的心律失常；而使用抗炎药物后 ...

Core Insights - The article discusses a groundbreaking study on cardiovascular disease, highlighting the limitations of existing laboratory models in accurately replicating the complex environment of human arteries [2][5] - The research introduces a novel extrusion-on-demand (EoD) bioprinting technology that creates arterial models with micron-level structural fidelity and customizable macro geometries, enabling better understanding of vascular disease mechanisms and personalized treatment approaches [3][8] Summary by Sections Research Background - Cardiovascular disease is the leading cause of death globally, yet research has been hindered by inadequate laboratory models that fail to replicate the intricate interactions involved in vascular diseases [2] - Current models are either overly simplified (2D) or lack the necessary structural and functional complexity (3D), leading to unresolved mechanisms and ineffective drug trials [2] Technological Innovation - The EoD bioprinting technology developed in this study allows for the construction of arterial models that accurately reflect the microenvironment of vascular diseases, including specific gene/protein expressions that enhance endothelial function and barrier integrity [5][6] - This technology bridges the gap between simplified in vitro systems and the complex in vivo environments, providing a biomimetic platform for disease mechanism analysis and therapy evaluation [5][9] Key Findings - The printed arterial models successfully replicate hallmark processes of vascular diseases, such as endothelial dysfunction, immune cell infiltration, and foam cell formation under physiologically relevant flow and inflammatory conditions [8][9] - The response of these models to drugs mirrors in vivo results, establishing their value for preclinical testing and therapeutic discovery [8] Implications for Future Research - This research not only presents a sophisticated vascular model but also offers a blueprint for engineering complex disease environments, paving the way for decoding vascular disease progression, identifying therapeutic targets, and accelerating precision medicine [9]